Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

662662

registered interest
date	20/12/2016
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	State Retirement Pensions: British Nationals Abroad
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they will give an assurance to UK citizens living in the EU and in receipt of the UK basic state pension that they will continue to receive the annual pension increase when the UK leaves the EU.
tabling member printed	Lord Jones of Cheltenham
uin	HL4269
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>Negotiating the details of the UK’s exit will take some time. The status of pensioners will need careful consideration and state pensions will be considered as part of the negotiations.</p> answering member printed Lord Freud question first answered 21/12/2016 12:54:32 answering member 3893 label Biography information for Lord Freud
tabling member	248 label Biography information for Lord Jones of Cheltenham

662032

registered interest
date	19/12/2016
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Unmanned Air Vehicles
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they intend to remove restrictions on the acquisition of equipment by members of the public which is capable of disabling or destroying drones flying over their property.
tabling member printed	Lord Blencathra
uin	HL4202
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>The Government recognises that an increase in the popularity of small drones, including those with cameras, raises a number of questions about privacy, safety, security, and data protection. Safety, security and privacy must always be the overriding priority and both commercial and leisure operators must operate drones responsibly within the rules.</p><p> </p><p>The Government is today launching a consultation to determine if further measures are needed in this area.</p> answering member printed Lord Ahmad of Wimbledon question first answered 21/12/2016 13:38:32 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
tabling member	497 label Biography information for Lord Blencathra

662033

registered interest
date	19/12/2016
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Unmanned Air Vehicles
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by the Minister of State for Transport on 10 September 2015 (HC7971), what action the cross-government working group has taken to reduce the risks posed by drones to civil aviation; and whether they plan to consult on the introduction of new criminal offences relating to (1) causing a nuisance, (2) endangering persons on the ground, and (3) endangering aircraft, through use of a drone.
tabling member printed	Lord Blencathra
uin	HL4203
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>We have been working closely with the Civil Aviation Authority and industry to adapt and strengthen regulations and implement mitigations as drones use and the related technology evolves. This has led to a new safety awareness campaign aimed at leisure drone users. So far, this has included the launch of a new <a href="http://www.dronesafe.uk" target="_blank">www.dronesafe.uk</a> website, a #400ftBritain drone photography competition that highlights safety rules, and a free new app ‘Drone Assist’ by NATS, which shows users where they should and should not fly in their locality. There are already offences to deter and, if necessary, prosecute operators for malicious or negligent use, including a prison sentence of up to five years for endangering an aircraft.</p><p> </p><p>The Government is today launching a consultation to determine if further measures are needed in this area.</p> answering member printed Lord Ahmad of Wimbledon question first answered 21/12/2016 13:46:47 answering member 4210 label Biography information for Lord Ahmad of Wimbledon
tabling member	497 label Biography information for Lord Blencathra

662066

registered interest
date	19/12/2016
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Disadvantaged
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether the proposed green paper on Social Justice will give consideration to the enactment of section 1 of the Equality Act 2010.
tabling member printed	Baroness Lister of Burtersett
uin	HL4234
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>The Prime Minister is clear that tackling poverty and disadvantage, and delivering real social reform, is a priority for this Government.</p><p> </p><p>The Department for Work and Pensions is leading work across Government to bring forward a social justice green paper in the New Year. This will identify and address the root causes of poverty, building upon the two statutory indicators set out in the Welfare Reform and Work Act 2016.</p> answering member printed Lord Freud question first answered 21/12/2016 13:54:12 answering member 3893 label Biography information for Lord Freud
tabling member	4234 label Biography information for Baroness Lister of Burtersett

662068

registered interest
date	19/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Per Capita Costs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the ranking of spending on healthcare per capita amongst EU member states.
tabling member printed	Lord Moonie
uin	HL4236
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>The latest Organisation for Economic Co-operation and Development (OECD) figures for total, per capita expenditure on healthcare that have been provided by the countries themselves are for 2014. These figures are only available for the 22 European Union member states that are also members of the OECD. They indicate that the United Kingdom ranked 10<sup>th</sup> out of 22 for total, per capita expenditure on healthcare in 2014. Rankings for all 22 EU member states that are also members of the OECD can be found in Table 1.</p><p> </p><p>OECD estimates for 2015 from their ‘Health at a Glance: Europe 2016’ report suggest that the United Kingdom’s ranking remains unchanged at 10<sup>th</sup> out of all 28 EU member states and that total, per capita expenditure on healthcare is slightly above the EU28 average. However, these figures are yet to be verified by the United Kingdom and a further 19 countries in the report.</p><p> </p><p> </p><p> </p><p>Table 1: Per capita expenditure on healthcare by the 22 EU member states that are also members of the OECD in 2014 - all functions, all financing schemes and all providers (current prices and current purchasing power parity)</p><table><tbody><tr><td><p>Country</p></td><td><p>Rank - 2014</p></td></tr><tr><td><p>Austria</p></td><td><p>6</p></td></tr><tr><td><p>Belgium</p></td><td><p>8</p></td></tr><tr><td><p>Czech Republic</p></td><td><p>16</p></td></tr><tr><td><p>Denmark</p></td><td><p>7</p></td></tr><tr><td><p>Estonia</p></td><td><p>20</p></td></tr><tr><td><p>Finland</p></td><td><p>11</p></td></tr><tr><td><p>France</p></td><td><p>9</p></td></tr><tr><td><p>Germany</p></td><td><p>3</p></td></tr><tr><td><p>Greece</p></td><td><p>17</p></td></tr><tr><td><p>Hungary</p></td><td><p>19</p></td></tr><tr><td><p>Ireland</p></td><td><p>5</p></td></tr><tr><td><p>Italy</p></td><td><p>12</p></td></tr><tr><td><p>Latvia</p></td><td><p>22</p></td></tr><tr><td><p>Luxembourg</p></td><td><p>1</p></td></tr><tr><td><p>Netherlands</p></td><td><p>2</p></td></tr><tr><td><p>Poland</p></td><td><p>21</p></td></tr><tr><td><p>Portugal</p></td><td><p>15</p></td></tr><tr><td><p>Slovak Republic</p></td><td><p>18</p></td></tr><tr><td><p>Slovenia</p></td><td><p>14</p></td></tr><tr><td><p>Spain</p></td><td><p>13</p></td></tr><tr><td><p>Sweden</p></td><td><p>4</p></td></tr><tr><td><p>United Kingdom</p></td><td><p>10</p></td></tr></tbody></table><p> </p><p>Source: OECD.Stat, Health Expenditure and Financing, 2014.</p> answering member printed Lord Prior of Brampton question first answered 21/12/2016 13:57:47 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	621 label Biography information for Lord Moonie

662093

registered interest
date	19/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuroblastoma
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they plan to uphold the verdict of the National Institute for Health and Clinical Excellence with regard to dinutuximab for children with neuroblastoma.
tabling member printed	Baroness Masham of Ilton
uin	HL4261
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet published its final guidance on dinutuximab (Unituxin) as a maintenance treatment after therapy for high-risk neuroblastoma. NICE’s Appraisal Committee is currently considering its draft guidance in light of the Appeal Panel’s decision to uphold an appeal against its final appraisal determination.</p><p> </p><p>Dinutuximab was referred to NICE under the single technology appraisal programme following its consideration through the established topic selection process including a public consultation and a scoping workshop with stakeholders.</p><p> </p><p>NICE is also currently appraising another anti-GD2 antibody product, APN311, for use in the treatment of high-risk neuroblastoma. APN311 is not yet licensed for use in the United Kingdom and has only been available in the UK in clinical trials.</p><p> </p><p>Neither treatment has been routinely commissioned for National Health Service patients in England.</p> answering member printed Lord Prior of Brampton grouped question UIN HL4262 HL4263 question first answered 21/12/2016 13:55:28 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1850 label Biography information for Baroness Masham of Ilton

662094

registered interest
date	19/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuroblastoma
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government why dinutuximab was referred to the National Institute for Health and Clinical Excellence under the Single Technology Appraisal methodology and not the Highly Specialised Technology programme.
tabling member printed	Baroness Masham of Ilton
uin	HL4262
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet published its final guidance on dinutuximab (Unituxin) as a maintenance treatment after therapy for high-risk neuroblastoma. NICE’s Appraisal Committee is currently considering its draft guidance in light of the Appeal Panel’s decision to uphold an appeal against its final appraisal determination.</p><p> </p><p>Dinutuximab was referred to NICE under the single technology appraisal programme following its consideration through the established topic selection process including a public consultation and a scoping workshop with stakeholders.</p><p> </p><p>NICE is also currently appraising another anti-GD2 antibody product, APN311, for use in the treatment of high-risk neuroblastoma. APN311 is not yet licensed for use in the United Kingdom and has only been available in the UK in clinical trials.</p><p> </p><p>Neither treatment has been routinely commissioned for National Health Service patients in England.</p> answering member printed Lord Prior of Brampton grouped question UIN HL4261 HL4263 question first answered 21/12/2016 13:55:28 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1850 label Biography information for Baroness Masham of Ilton

662095

registered interest
date	19/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Neuroblastoma
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what steps they are taking to restore the availability of, and access to, the anti-GD2 antibody which had previously been approved.
tabling member printed	Baroness Masham of Ilton
uin	HL4263
answer	answer is ministerial correction date of answer 21/12/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) has not yet published its final guidance on dinutuximab (Unituxin) as a maintenance treatment after therapy for high-risk neuroblastoma. NICE’s Appraisal Committee is currently considering its draft guidance in light of the Appeal Panel’s decision to uphold an appeal against its final appraisal determination.</p><p> </p><p>Dinutuximab was referred to NICE under the single technology appraisal programme following its consideration through the established topic selection process including a public consultation and a scoping workshop with stakeholders.</p><p> </p><p>NICE is also currently appraising another anti-GD2 antibody product, APN311, for use in the treatment of high-risk neuroblastoma. APN311 is not yet licensed for use in the United Kingdom and has only been available in the UK in clinical trials.</p><p> </p><p>Neither treatment has been routinely commissioned for National Health Service patients in England.</p> answering member printed Lord Prior of Brampton grouped question UIN HL4261 HL4262 question first answered 21/12/2016 13:55:28 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1850 label Biography information for Baroness Masham of Ilton

660096

registered interest
date	16/12/2016
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	CaTreasury
hansard heading	Off-payroll Working
house id	1
legislature	25259 pref label House of Commons
question text	To ask Mr Chancellor of the Exchequer, when he plans to issue a response to the Intermediaries Legislation (IR35): discussion document, published in July 2015.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	58072
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Government’s response to the summer 2015 discussion document was published on 26 July 2016 as part of the consultation 'off-payroll working in the public sector: reform of the intermediaries legislation'. A document summarising responses to the July 2016 consultation was published in December 2016. Both documents can be accessed here: <a href="https://www.gov.uk/government/consultations/off-payroll-working-in-the-public-sector-reform-of-the-intermediaries-legislation" target="_blank">https://www.gov.uk/government/consultations/off-payroll-working-in-the-public-sector-reform-of-the-intermediaries-legislation</a></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 20/12/2016 14:16:17 answering member 3918 label Biography information for Jane Ellison
tabling member	253 label Biography information for Mr Laurence Robertson

660101

registered interest
date	16/12/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Carers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent estimate he has made of the effect that providing unpaid care has on the personal finances of adult and young carers.
tabling member constituency	Glasgow East
tabling member printed	Natalie McGarry
uin	58013
answer	answer is ministerial correction date of answer 20/12/2016 answer text <p>The Department uses a range of publicly available data to inform its understanding of informal care, including:</p><p>- The United Kingdom 2011 Census asked about provision of unpaid care by age and number of hours provided. Separate data is available for England, Scotland, Wales and Northern Ireland.</p><p>- The UK Family Resources Survey provides a breakdown by age, gender and hours of care provided. Separate data is available for England, Scotland, Wales and Northern Ireland.</p><p>- The Health Survey for England 2014 provides details of hours of care provided, with a breakdown by age and gender. Data is also included on the types of caring task undertaken.</p><p>- The Personal Social Services Survey of Adult Carers in England 2014-15 surveys those carers known to local authorities in England, and includes data on the support needs of the person being cared for. Data is also included on the types of caring task undertaken.</p><p>- The Survey of Carers in Households 2009-10 includes some details of the support needs of the person being cared for, with some additional information on hours of care provided.</p><p>- The Office for National Statistics Household Satellite Accounts includes a specific module on the economic value of informal adult care. Separate data is available for England, Scotland, Wales and Northern Ireland.</p><p>In addition, the Department is currently leading the development of a new cross-Government Carers Strategy, due for publication in 2017. To inform this, the Department has recently undertaken a wide ranging <em>Call for Evidence</em> to gather the views and experiences of carers and other stakeholders, and to supplement the significant amount of publicly available data. This included asking carers directly about their caring roles and experiences, including the impact on their finances, and any health need or disability they may have that affects their caring role.</p><p> </p><p>The <em>Call for Evidence</em> also included new research commissioned by the Department from the Economics of Social Care and Health Research Unit to estimate the future demand for informal care, and the likely availability of informal care in England. This research will supplement existing data from previous work by the Personal Social Services Research Unit.</p><p> </p><p>Alongside the <em>Call for Evidence</em>, the Department for Education has commissioned new research to improve understanding of the numbers and needs of young carers and their families, carried out by TNS BMRB Research in partnership with Loughborough University. This research includes a qualitative strand, entitled ‘<em>The Lives of Young Carers in England</em>’ published in February 2016; and quantitative work to be published before the end of this year that will provide information on the nature of the care and support that young carers are providing; the perceived impact of caring responsibilities on physical and mental health, education and development; and the types of support that young carers receive.</p><p> </p><p>The Department of Health is currently working with stakeholders to develop the new Carers Strategy. This will set out the findings from the <em>Call for Evidence</em>, and the priorities and actions contained in the Strategy will therefore be based on an assessment of this wide evidence base as well as the range of published qualitative evidence of the issues of most concern to carers.</p> answering member constituency Warrington South answering member printed David Mowat grouped question UIN 57855 57859 57959 57960 57961 question first answered 20/12/2016 16:29:55 answering member 4080 label Biography information for David Mowat
tabling member	4428 label Biography information for Natalie McGarry